A multicenter case-control study of the effect of e-nos VNTR polymorphism on upper gastrointestinal hemorrhage in NSAID users by Mallah, Narmeen et al.
1
Vol.:(0123456789)
Scientific Reports |        (2021) 11:19923  | https://doi.org/10.1038/s41598-021-99402-w
www.nature.com/scientificreports
A multicenter case–control 
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Bleeding in non‑steroidal anti‑inflammatory drug (NSAID) users limited their prescription. This 
first multicenter full case–control study (325 cases and 744 controls), explored the association of 
e‑NOS intron 4 variable number tandem repeat (VNTR) polymorphism with upper gastrointestinal 
hemorrhage (UGIH) in NSAID exposed and unexposed populations and assessed any interaction 
between this polymorphism and NSAIDs. NSAID users carrying e‑NOS intron 4 wild type genotype or 
VNTR polymorphism have higher odds of UGIH than those unexposed to NSAIDs [Odds Ratio (OR): 
6.62 (95% Confidence Interval (CI): 4.24, 10.36) and OR: 5.41 (95% CI 2.62, 11.51), respectively], with 
no effect modification from VNTR polymorphism‑NSAIDs interaction [Relative Excess Risk due to 
Interaction (RERI): −1.35 (95% CI −5.73, 3.03); Synergism Index (S): 0.77 (95% CI 0.31, 1.94)]. Similar 
findings were obtained for aspirin exposure. Non‑aspirin NSAID users who carry e‑NOS intron 4 VNTR 
polymorphism have lower odds of UGIH [OR: 4.02 (95% CI 1.85, 8.75) than those users with wild 
type genotype [OR: 6.52 (95% CI 4.09, 10.38)]; though the interaction estimates are not statistically 
significant [RERI: −2.68 (95% CI −6.67, 1.31); S: 0.53 (95% CI 0.18, 1.55)]. This exploratory study 
suggests that the odds of UGIH in NSAID or aspirin users does not modify according to patient´s 
e‑NOS intron 4 genotype.
Aspirin and non-aspirin non-steroidal anti-inflammatory drugs (NSAIDs) are among the most frequently used 
therapeutic agents for a wide variety of indications due to their effectiveness and cost-efficiency1–3. The use of 
aspirin, an archetype of NSAIDs, in secondary prevention against cardiovascular diseases is well  established4. 
Recent reports also demonstrated that the beneficial effects of NSAIDs and aspirin extend to a reduced risk of 
other major diseases including digestive tract cancers, hepatocellular carcinoma, cholangiocarcinoma, breast 
cancer, pancreatitis and liver  fibrosis5–10. However, the idiosyncratic effects manifested by susceptible individuals, 
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mainly gastrointestinal bleeding, have limited the application of NSAIDs and aspirin in primary  prevention11–13. 
Gastrointestinal bleeding remains a major medical concern as it is among the main causes of hospitalizations 
related to digestive diseases in several  countries14. Non-variceal upper gastrointestinal hemorrhage (UGIH) 
represents a serious medical challenge worldwide, with an incidence of 48 to 160 cases per 100,000 adults per 
year and a mortality rate ranging between 1.1% and 11%15.
Nonetheless, a general discontinuation of NSAIDs or aspirin use might not be a sufficient solution. A recent 
cohort study of low-dose aspirin for primary or secondary prevention against cardiovascular diseases showed that 
the cessation of aspirin therapy in patients free from major surgery or bleeding increases the risk of cardiovas-
cular events by more than 30%16. Accordingly, a combination of pharmacogenetic and pharmacoepidemiologic 
studies is needed to assess and improve the use of personalized NSAIDs treatment.
Gastrointestinal bleeding in patients who use NSAIDs and aspirin was associated with genetic 
 polymorphisms17–22. In the gastrointestinal tract, vasodilation and mucosal blood flow are mediated by Nitric 
Oxide (NO). Prostaglandins also exert a fundamental role in protecting the gastric mucosa from  damage23. 
Circulating NO is mainly produced by endothelial NO synthase (e-NOS) and plays a fundamental role in pro-
tecting the gastric mucosa, repairing gastric damage induced by NSAIDs and aspirin, regulating blood flow, 
fostering angiogenesis, preventing thrombosis, cardiac or vascular contractility, controlling cardiovascular tissue 
remodeling, and inhibiting platelet  aggregation24–27. Reduced bioavailability of NO predisposes to hypertension, 
thrombosis and  vasospasm28.
Genetic variations in e-NOS influence the expression of this gene, and thus could modify drug response and 
influence the development of some  diseases24,26,29. In specific, the levels of NO in the plasma are significantly 
affected by genetic variations in intron 4 of e-NOS  gene30. The 27-base pairs (bp) variable number of tandem 
repeat (VNTR) polymorphism in this intron represents a type of these genetic variations. VNTRs are sequences 
of DNA with a high degree of polymorphism among individuals in the length of repeated nucleotides that lie 
adjacent to each other in the  genome31. The ancestral allele of e-NOS intron 4 VNTR polymorphism consists of 
five repeats of the 27 bp segment and is known as “4b”, whereas its variant comprises a tandem of four repeats 
of the 27 bp sequence and is denoted “4a”24,30.
The allele 4a was previously associated with a lower risk of UGIH in aspirin  users32. Nonetheless, the protec-
tive effect of this e-NOS genetic variant against UGIH was determined in a study that included a selective group 
of patients exposed to  aspirin32. The lack of data about individuals unexposed to aspirin in that  study32, makes 
it impossible to determine whether the reported reduced risk of UGIH is due to a protective effect of 4a e-NOS 
allele itself or generated from a modification of effect from an interaction between this genetic variation and 
aspirin, in which case, further investigation is needed.
Accordingly, in this study, we aimed to explore the association of e-NOS intron 4 VNTR polymorphism with 
UGIH in a population composed of patients exposed and unexposed to NSAIDs. In addition, we investigated 
the effect modification by 4a and 4b alleles on NSAIDs-related UGIH. We also performed a stratified analysis 
by type of NSAIDs (i.e. any NSAIDs, aspirin NSAIDs and non-aspirin NSAIDs).
2. Methods.
Study design and population. We carried out a multicenter, full case–control study. Three hundred 
twenty-five cases and 744 controls were prospectively recruited (incident cases) from four health centers in 
Spain in two different waves (2004–2007, and 2013–2015).
Cases were defined as patients admitted to the hospital for UGIH, diagnosed surgically or endoscopically. 
All eligible UGIH cases of any grade of severity were included.
Controls were patients who had a programmed unpainful surgery (such as prostatic adenoma, eye cataract, 
ear pinning, lipoma, vocal cord cyst, septoplasty and thyroid nodules) that was not related to NSAID exposure.
Adults (> 18 years old), of European origin, and biologically unrelated cases and controls were recruited from 
the same health centers. We used the native tongue of the participants or the original language of their parents 
as a proxy of  ethnicity33–36.
Cases and controls were matched on age, sex, recruiting health center and period of recruitment. We used 
the same protocol as that of two related studies published  previously21,37.
Participants were interviewed by trained health personnel using a comprehensive questionnaire that was 
specifically designed for this study. The questionnaire included questions about the consumed medicines, source 
of prescriptions and indications of use, recurrent symptoms for which NSAIDs were recommended and the pre-
scribed treatments to alleviate these symptoms. It also included questions about caffeine consumption, dietary 
habits, alcohol intake and tobacco smoking. Prompt cards of commercial NSAIDs (aspirin and non-aspirin 
NSAIDs) boxes were used to help the participant identify and recall better the use of these drugs. All NSAIDs 
were considered for the analysis, irrespective of their route of administration. The interview was repeated on 
subsequent dates when needed, such as in case of the patient’s tiredness to complete the whole interview and/
or failure to remember some information.
The reliability of the interview was rated using a 0–10 Likert scale as perceived by the interviewer. To confirm 
that NSAID exposure took place prior to any symptom of UGIH, an index date of NSAID use was defined. For 
cases, the index date was the day of occurrence of the first symptoms of UGIH, whereas it was the recruitment 
date for the controls. We determined the index date by relying on the patient’s clinical history, but the researchers 
were blind to patient’s exposure to NSAIDs. In line with previous related studies, a seven-day etiologic window 
was established starting from the index  date38–40.
All participants were tested for the presence of anti-Helicobacter pylori immunoglobulin G using enzyme 
linked immunosorbent assay (ELISA). The following commercial kits were applied according to the manufac-
turer’s protocol [Human Anti-Helicobacter pylori IgG ELISA Kit (ab108736, Abcam, Cambridge, England), and 
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Captia™ H. pylori IgG EIA (ref: 2,346,400, Trinity Biotech Captia, Co. Wicklaw, Ireland)]. Participants were asked 
whether they have ever been treated against Helicobacter pylori infection in order to avoid having any false posi-
tive result from a previous infection.
Genotyping. The eNOS intron 4 VNTR polymorphism was detected by polymerase chain reaction (PCR) 
using the following primers: 5′-AGG CCC TAT GGT AGT GCC TTT-3′ and 5′-TCT CTT AGT GCT GTG GTC 
AC-3′41–43. The reaction mixture (a total volume of 25 µl) contained 2.5 µl of 10 × PCR buffer, including 100 ng 
of genomic DNA, 1.5 mM MgCl2, 0.2 mM of each dNTP, 500 nmol of each primer and 5 U Taq polymerase. 
PCR was performed with 35 cycles of 30 s at 94 °C for denaturation, 30 s at 63 °C for annealing, and 1 min at 
72 °C for extension, followed by final extension for 5 min at 72 °C. The following fragments were produced: 
393 bp band (4 copies of the 27 bp repeat), and 420 bp band (5 copies of the 27 bp repeat). The amplified product 
was size fractionated by the D1000 Screen Tape assay (Agilent Technologies, CA) on Agilent 4200 TapeStation 
system according to manufacturer’s recommendations. For quality control, 5% of the samples were selected to 
repeat PCR and genotyping, and no discrepancies were found. All cases and controls were genotyped using a 
phenotype-blind process. Hardy–Weinberg equilibrium was tested in the control group (significance thresh-
old: P-value < 0.001), using SNPassoc Library of the R  package44, to check for possible bias in the selection of 
 controls45,46.
Statistical analysis. The 27 bp e-NOS intron 4 VNTR polymorphism was genotyped for all participants 
who were then stratified into four categories according to NSAID exposure (exposed/unexposed) and genotype 
(wild type/genetic variation). The wild type genotype was denoted “b allele” and defined as five copies of the 
27 bp repeats in both alleles (5/5). The genetic variant was denoted “a allele” when characterized by four copies 
of the 27 bp repeats in both alleles (4/4) or “ab allele” in case of possessing four copies of the 27 bp repeats in one 
allele and five copies of the same repeat in the second allele (4/5). The group that comprised patients who were 
“unexposed to NSAIDs and carriers of the wild type genotype” was used as a reference category.
Adjusted Odds Ratios (OR) of UGIH and their 95% Confidence Intervals (CI) were estimated using the 
generalized linear mixed models for dependent binomial variables. The statistical models were constructed by 
considering the following four consecutive levels: patient, strata of cases and controls (each case and its matched 
controls), health center, and period of patients’ recruitment. We used a random-effects model to assess the effect 
of the period of patients’ recruitment and a nested random-effects model for the strata of cases and controls, and 
health center. The models were estimated using the lmer function of the lme4 R  package47. Initially, in univariate 
analysis, we explored the effect of potential confounders including age, Body Mass Index (BMI), sex, tobacco 
smoking, alcohol intake, caffeine consumption, diet, previous history of arthrosis and/or gastrointestinal dis-
orders other than UGIH, Helicobacter pylori infection, source of information (i.e. whether the interview was 
answered by the patient independently or with the help of a healthcare assistant / direct relatives), number of 
undertaken interviews, reliability of the interview as perceived by the interviewer, and exposure to medications 
that are not NSAIDs. Potential confounders were retained in the model if they changed the OR of the main 
variable by at least 10%, and provided that the Schwartz’s Bayesian Information Criterion was  enhanced48,49.
Subsequently, the additive interaction effect between e-NOS intron 4 VNTR polymorphism and NSAIDs 
on UGIH was determined by calculating the Relative Excess Risk due to Interaction (RERI) and the Synergism 
Index (S) estimates along with their 95% CI.
We also undertook a stratified analysis by type of NSAIDs where we assessed the effect of e-NOS VNTR 
polymorphism on UGIH in 1) non-aspirin NSAIDs users, and 2) aspirin NSAIDs users.
Ethical aspects. Participants signed a written informed consent before their enrolment in the study.
Ethics approval. The study was approved by the ethics committee for clinical research of each participat-
ing health center: Barcelona (CEIC; protocol number: Es38121226Z), Euskadi (CEIC-E; protocol number: 
PI2013101), Galicia (CEIC-G; protocol number: 2013/263) and Valladolid (CEIC-VA-ESTE-HCUV; protocol 
number: PI-14–142). All procedures were performed in accordance with the 1964 Helsinki declaration and 
comparable ethical standards.
Results
General patients’ characteristics. Three hundred twenty-five cases and 744 controls fulfilled the inclu-
sion criteria and were included in the study. Their demographic and clinical characteristics are presented in 
Table 1.
Genotyping. The genotyping was successful for all 1069 participants. Table 2 represents the distribution of 
the wild type and the polymorphic genotypes across cases and controls.
The homozygous genotype (420 bp/420 bp) denoted by “b” allele was the most prevalent in our study popula-
tion [247 cases (76%) and 550 (73.9%) controls] (Table 2). Accordingly, “b” allele was deemed as the ancestral 
wild type allele.
Seventy-eight (24%) cases and 194 (26.1%) controls carried genetic variants of e-NOS intron 4 VNTR poly-
morphism. The controls followed Hardy–Weinberg equilibrium (p-value = 0.025).
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Association of e‑NOS VNTR polymorphism with UGIH. Table 3 summarizes the association of NSAID, 
non-aspirin NSAID and aspirin use with UGIH, stratified by e-Nos intron 4 genotype (wild type/genetic vari-
ation).
Table 1.  Clinical and demographic characteristics of the study population. CI, confidence interval; N, number 
of participants; OR, odds ratio.
Characteristic Cases (N = 325) N (%) Controls (N = 744) N (%) OR (95% CI)
Study period
EMPHOGEN 1 (2004–2007) 253 (77.8%) 590 (79.3%) 0.71 (0.51, 0.99)
EMPHOGEN 2 (2013–2015) 72 (22.2%) 154 (20.7%) 1
Age
 < 45 41 (12.6%) 95 (12.8%) 1
45–65 116 (35.7%) 267 (35.9%) 1.06 (0.68, 1.65)
 > 65 161 (49.5%) 370 (49.7%) 1.01 (0.66, 1.54)
Missing 7 (2.2%) 12 (1.6%) –
BMI
Underweight 10 (3.1%) 24 (3.2%) 0.73 (0.33, 1.61)
Normal weight 113 (34.8%) 202 (27.2%) 1
Overweight 128 (39.4%) 372 (50.0%) 0.61 (0.44, 0.83)
Obesity 68 (20.9%) 144 (19.4%) 0.84 (0.57, 1.23)
Missing 6 (1.8%) 2 (0.3%) –
Sex
Male 235 (72.3%) 556 (74.7%) 1
Female 87 (26.8%) 188 (25.3%) 1.18 (0.87, 1.61)
Missing 3 (0.9%) 0 –
Arthrosis
No 218 (67.1%) 466 (62.6%) 1
Yes 86 (26.5%) 215 (28.9%) 0.86 (0.63, 1.17)
Missing 21 (6.5%) 63 (8.5%)
Helicobacter pylori
No or inconclusive 27 (8.3%) 136 (18.3%) 1
Yes 275 (84.6%) 572 (76.9%) 2.52 (1.60, 3.96)
Missing 23 (7.1%) 36 (4.8%)
Source of information
Patients 258 (79.4%) 668 (89.8%) 1
Healthcare assistants / direct relatives 67 (20.6%) 76 (10.2%) 2.34 (1.61, 3.41)
Interview variables
Number of interviews conducted
1 273 (84.0%) 640 (86.0%) 1
 ≥ 2 52 (16.0%) 104 (13.9%) 1.27 (0.81, 2.00)
Reliability of the interview
 < 5 13 (4.0%) 20 (2.7%) 1
5–7 36 (11.1%) 77 (10.3%) 0.68 (0.30, 1.55)
7–9 134 (41.2%) 310 (41.7%) 0.70 (0.33, 1.48)
 ≥ 9 142 (43.7%) 337 (45.3%) 0.67 (0.32, 1.41)
Personal history of gastrointestinal disorders
None or dyspepsia 207 (63.7%) 644 (86.6%) 1
Ulcer 48 (14.8%) 55 (7.4%) 2.78 (1.81, 4.27)
Bleeding 70 (21.5%) 45 (6.0%) 4.77 (3.14, 7.25)
Exposure to other medications
Inhibitors of COX2 3 (0.9%) 6 (0.8%) 0.88 (0.21, 3.75)
Analgesics not narcotics 54 (16.6%) 56 (7.5%) 2.72 (1.80, 4.13)
Inhibitors of the proton pump 36 (11.1%) 65 (8.7%) 1.21 (0.77, 1.90)
Antiaggregant 65 (20.0%) 86 (11.6%) 1.93 (1.33, 2.79)
Anticoagulants 35 (10.8%) 32 (4.3%) 3.07 (1.84, 5.13)
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No association was observed between the polymorphic alleles of e-NOS intron 4 VNTR and UGIH in patients 
unexposed to any NSAID [OR: 1.14 (95% 0.74, 1.74)], non-aspirin NSAIDs [OR: 1.18 (95% 0.78, 1.78)] and 
aspirin [OR: 1.03 (95% CI 0.70, 1.51)] (Table 3).
Modification of the effect of NSAIDs on UGIH by e‑NOS VNTR polymorphism. As shown in 
Table 3, an association was observed between exposure to any NSAID and UGIH. Nonetheless, no substantial 
difference in the magnitude of this association was detected between NSAIDs users with e-NOS intron 4 wild 
type genotype [OR: 6.62 (95% CI 4.24, 10.36)] and those users with e-NOS intron 4 VNTR polymorphism [OR: 
5.41 (95% CI 2.62, 11.15)].
Similar findings were obtained for aspirin exposure by individuals carrying the wild type genotype [OR: 
5.17 (95% CI 2.11, 12.68)] and by individuals carrying the genetic variants of e-NOS intron 4 [OR: 5.80 (95% 
CI 1.32, 25.46)] (Table 3).
Regarding exposure to non-aspirin NSAIDs, patients carrying e-NOS intron 4 VNTR polymorphism have 
lower odds of UGIH than non-aspirin NSAID users with wild type genotype of e-NOS intron 4 [OR: 4.02 (95% 
CI 1.85–8.75) and OR: 6.52 (95% CI 4.09, 10.38), respectively] (Table 3).
Our exploratory analysis suggests that there is no interaction between e-NOS intron 4 VNTR polymorphism 
and any NSAID on UGIH. We also did not observe an interaction between e-NOS intron 4 VNTR polymorphism 
and aspirin exposure. However, our findings reveal decreased odds of UGIH from a potential interaction between 
e-NOS intron 4 VNTR polymorphism and non-aspirin NSAID use, though the interaction estimates were not 
statistically significant [RERI: −2.68 (95% CI −6.67, 1.31); S: 0.53 (95% CI 0.18, 1.55)].
Table 2.  Distribution of wild type and polymorphic alleles of e-NOS intron 4 VNTRs polymorphism across 
cases and controls. a Others group included the following genetic variations: 420 bp/447 bp (3 cases and 2 
controls), 366 bp/420 bp (1 control) and 370 bp/420 bp (1 control).
Genotype
Cases (N = 325)
N (%)
Controls (N = 744)
N (%)
Wild type
homozygous “b” (420 bp/420 bp) 247 (76%) 550 (73.9%)
Genetic variation
heterozygous “ab” (393 bp/420 bp) 67 (20.6) 167 (22.4%)
homozygous “a” (393 bp/393 bp) 8 (2.5%) 23 (3.1%)
Othersa 3 (0.9%) 4 (0.5%)
Table 3.  Effect of e-NOS intron 4 VNTR polymorphism and NSAIDs exposure on the risk of UGIH. CI, 
confidence interval; N, number of participants; OR odds ratio; RERI, Relative Excess Risk due to Interaction; 
S, Synergism Index. a Odds Ratio adjusted for: period of patients’ recruitment, previous history of arthrosis, 
infection with Helicobacter pylori, gastrointestinal disorders (ulcer and bleeding), exposure to inhibitors of the 
proton pump, exposure to antiaggregant, exposure to anticoagulants, the number of conducted interviews, and 
the reliability of the interview. Aspirin subgroup analysis was additionally adjusted for exposure to non-aspirin 
NSAIDs. RERI = 0 and S = 1 imply no interaction, RERI > 0 and S > 1 imply positive interaction and RERI < 0 
and S < 1 imply negative interaction.
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Discussion
Numerous studies associated the risk of gastrointestinal bleeding with genetic polymorphisms. However, there 
is a lack of knowledge about the influence of genetic variation on UGIH from NSAID and aspirin exposure. 
eNOS gene is known to exert fundamental activities in protecting gastric mucosa and repairing NSAIDs/aspi-
rin-caused damage. Nevertheless, there is a shortage of information about the effect of variations in this gene 
on drug  response26. In a recent study on the effect of polymorphisms on aspirin-related UGIH, we suggested 
that aspirin users who carry the inherited allele of rs1799983 polymorphism of NOS3 gene have lower odds of 
 UGIH21. Therefore, in this multicentre case–control study, we conducted an exploratory analysis of the effect 
of eNOS intron 4 VNTR polymorphism on UGIH in users and non-users of NSAIDs (any NSAID, non-aspirin 
and aspirin NSAIDs).
The findings of this study reveal that genetic variants of e-NOS intron 4 VNTR polymorphism might not 
interact with aspirin and consequently, they might not modify the odds of UGIH in aspirin users. Our results 
also suggest a potentially decreased odds of UGIH in users of non-aspirin NSAIDs who carry the polymorphic 
genotype of e-NOS intron 4 VNTR. The interaction between non-aspirin NSAIDs and e-NOS intron 4 VNTR 
polymorphism was not statistically significant, hence, these secondary findings should be considered explora-
tory and interpreted with caution until replicated in a larger study. If these findings were confirmed, it would 
mean that the odds of UGIH in any NSAID users carrying e-NOS intron 4 VNTR polymorphism could be 
overestimated due to the inclusion of aspirin users. They would also allow better management of non-aspirin 
NSAID personalized medicine.
At the molecular level, the production of NO, a mediator of various physiological functions in the gastroin-
testinal  tract27, seems to be affected by the genetic variation of 27-bp VNTR of e-NOS intron 4. The microRNA 
derived from this VNTR polymorphism suppresses e-NOS expression, and in specific the ancestral allele “4b” 
generates more microRNA and thus inhibits further the production of  NO24,50,51. On the contrary, the intake 
of low-dose aspirin increases NO production by blood vessels and stimulates e-NOS enzymatic  activity52. As 
e-NOS is the main isoform responsible for the regulation of vasodilation in the gastrointestinal system, it is 
expected that carrying the allelic variant 4a of e-NOS may reduce the risk of gastrointestinal bleeding. However, 
our exploratory analysis revealed that e-NOS intron 4 VNTR polymorphism is not associated with reduced odds 
of bleeding in aspirin users. This finding could be influenced by the limited number of individuals with e-NOS 
intron 4 VNTR polymorphism who were on aspirin treatment in our study. Due to the lack of full-case control 
studies (i.e., studies that encompass users and non-users of aspirin), we cannot compare our findings with those 
of other reports. However, it is crucial to highlight that our results differ from that of Piazuelo and colleagues who 
found an association between the genetic variant “4a” of e-NOS gene and lower odds of UGIH in aspirin  users32. 
The study of Piazuelo involved aspirin users exclusively, and thus the effect of 4a e-NOS allele on aspirin-related 
UGIH could not be  determined53. Accordingly, future larger studies are required to guarantee a comprehensive 
assessment of the effect of e-NOS intron 4 VNTR polymorphism on UGIH in users of aspirin and NSAIDs.
In general, the use of VNTR polymorphism in NSAID or aspirin personalized medicine has been very limited 
so far, although the high polymorphic characteristics of VNTR make them very informative in determining the 
loci for  diseases31. Research studies have mainly focused on investigating the effect of SNPs in complex diseases 
or studying drug  responses54. To date, only five studies have examined the association of VNTR polymorphism 
with aspirin and/or NSAIDs. These studies were carried out in different populations and targeted distinct health 
conditions, highlighting therefore the need for more research on the influence of VNTR polymorphism on 
NSAIDs- and aspirin-related UGIH (Table 4).
ALOX5, arachidonate 5-lipoxygenase; eNOS, endothelial nitric oxide synthase; FLAP, 5-lipoxygenase-acti-
vating protein; PGIS, prostacyclin synthase; UGIH, upper gastrointestinal haemorrhage.
Though our study is exploratory, it is characterized by various points of strength that might help designing 
future larger studies. Including both groups of participants “exposed and unexposed to NSAIDs” and stratifying 
by the type of NSAIDs (i.e., aspirin and non-aspirin) permitted providing a comprehensive assessment of these 
drugs. Adjusting the measures of effect for a large number of potentially confounding factors decreased the risk of 
confounding in these  estimates59. Limiting the analysis to a specific ethnic group (i.e., using the native tongue of 
the participant or the original mother/father language as a proxy of ethnicity) allowed avoiding bias due to ethnic 
differences. The inclusion of only biologically unrelated participants prevented bias from the over-representation 
of ancestral  alleles60. The use of catalogue of NSAIDs prompt cards during the interview aided the participants 
Table 4.  Summary of studies characteristics about the interaction between VNTRs and aspirin or NSAIDs.
Study Country Patients’ characteristics Health condition Gene Drug-gene interaction analysis
Kleinstein et al.55 United States NSAIDs exposed and nonexposed participants Colorectal carcinogenesis
ALOX5 and FLAP poly A pro-
moter repeat [-169(PolyA)] Yes
Piazuelo et al.32 Spain Aspirin exposed participants UGIH eNOS No
Poole et al.56 United States NSAIDs/aspirin exposed and nonexposed participants Colorectal polyps PGIS and ALOX5 Yes
Jin et al.57 China Aspirin exposed participants Aspirin resistance glycoprotein Ib α No
Cervera el al.58 Spain Aspirin exposed participants Aspirin treatment failure against Ischemic stroke glycoprotein Ib α No
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to recall and identify better the use of these drugs, and reviewing the medical records of the patients assisted in 
the reduction of the risk of recall bias.
Our findings need to be confirmed by larger studies and in different populations. Stratifying the study popu-
lation by drug exposure and genotype resulted in a limited number of UGIH cases and controls in each stra-
tum, especially in aspirin subgroup analysis, which was then reflected in the width of the estimated confidence 
intervals. The sample size limitation also precluded carrying out the initially planned dose–response analysis. 
Therefore, our findings correspond to any exposure to NSAIDs/aspirin. Reproducing the study in a larger popu-
lation would allow for (1) increasing the number of cases and controls per subgroup and consequently improv-
ing the statistical power of the observed associations and (2) undertaking further analysis such as evaluating a 
dose–response relationship. Furthermore, our results cannot be generalized to non-white European populations 
due to ethnic differences. Replicating the study in different ethnic groups would permit testing the association 
between e-NOS intron 4 VNTR polymorphism, NSAIDs and UGIH in genetically different populations.
In conclusion, this exploratory study suggests that exposure to NSAIDs or aspirin does not modify the odds 
of UGIH according to patient’s e-NOS intron 4 genotype. It also suggests that e-NOS intron 4 VNTR polymor-
phism might reduce the odds of UGIH in non-aspirin NSAID users. More research is needed to understand the 
pharmacogenetics of NSAIDs, especially aspirin, which possess a large spectrum of protective and prophylactic 
properties, and more room should be given to VNTR polymorphism in studies oriented towards personalized 
medicine.
Data availability
The datasets generated and analyzed for this study can be found in the FigShare Repository [https:// doi. org/ 10. 
6084/ m9. figsh are. 13109 663. v1].
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